Mass Overdoses from Synthetic Marijuana Remind Need for Public Education
August 16, 2018Canadian Cannabis Investor Never Bargained for Surprise Lifetime U.S. Ban
August 18, 2018Mass Overdoses from Synthetic Marijuana Remind Need for Public Education
August 16, 2018Canadian Cannabis Investor Never Bargained for Surprise Lifetime U.S. Ban
August 18, 2018
- The CBD Report 2018: Industry Outlook, details how the U.S. CBD industry grew nearly 40% in 2017, reaching $367 million in sales across both hemp-derived and marijuana-derived markets.
- For the first time in 2017, U.S. hemp-derived CBD products outsold marijuana-derived CBD products.
- Marijuana-derived CBD branded sales grew from $64M in 2016 to $118M in 2017, a one-year increase of 84%. They will account for nearly 80% of the market versus flower by 2020.
- The anticipated rollout of Epidiolex in September will open the pharmaceutical channel; by 2022 the juvenile epilepsy treatment will account for approximately 1/3 of the total CBD market, netting estimated sales of over $625M.
